Medical University of Vienna, Department of Traumatology, Waehringer Guertel 18-20, Vienna, A-1090 Austria.
Am J Sports Med. 2012 Oct;40(10):2273-80. doi: 10.1177/0363546512457008. Epub 2012 Aug 24.
To date, few studies have been published reporting the 5-year follow-up of clinical and radiological outcomes for chondral defects treated with matrix-induced autologous chondrocyte implantation (MACI).
A significant improvement in clinical and radiological outcomes after treatment of symptomatic, traumatic chondral defects of the knee with the MACI implant will be maintained up to 5 years after surgery.
Case series; Level of evidence, 4.
A prospective evaluation of the MACI procedure was performed in 21 patients with chondral defects of the knee. After the MACI procedure, patients were clinically assessed with the Knee injury and Osteoarthritis Outcome Score (KOOS), the Tegner-Lysholm score, the International Knee Documentation Committee (IKDC) Subjective Knee Form, and the modified Cincinnati score at years 1, 2, and 5. The quality of repair tissue was assessed by magnetic resonance imaging using the magnetic resonance observation of cartilage repair tissue (MOCART) score at months 3 and 6 and years 1, 2, and 5.
Significant improvements (P < .05) were observed for all 5 KOOS subcategories at year 1 and were maintained through year 5 in 90.5% of patients (19/21). Treatment failure occurred in only 9.5% of patients (2/21). Significant improvements (P < .05) from baseline to year 5 were also observed for the IKDC score (30.1 to 74.3), the modified Cincinnati score (38.1 to 79.6), and the Tegner-Lysholm activity score (1.8 to 4.3). Similarly, the MOCART score significantly improved (P < .001) from baseline to year 5 (52.9 to 75.8). After 5 years, complete filling (83%) and integration (82%) of the graft were seen in the majority of patients. Signs of subchondral bone edema were still present in 47% of patients at 5 years. No product-specific adverse events were reported over the 5-year follow-up period.
Patients treated with a MACI implant demonstrated significant clinical improvement and good quality repair tissue 5 years after surgery. The MACI procedure was shown to be a safe and effective treatment for symptomatic, traumatic chondral knee defects in this study.
迄今为止,仅有少数研究报道了采用基质诱导自体软骨细胞植入(MACI)治疗软骨缺损的 5 年临床和影像学结果。
采用 MACI 植入物治疗膝关节症状性创伤性软骨缺损,其临床和影像学结果在手术后 5 年内将持续得到改善。
病例系列;证据水平,4 级。
对 21 例膝关节软骨缺损患者进行了 MACI 手术的前瞻性评估。MACI 手术后,患者分别采用膝关节损伤和骨关节炎评分(KOOS)、Tegner-Lysholm 评分、国际膝关节文献委员会(IKDC)主观膝关节评分和改良辛辛那提评分,在第 1、2 和 5 年进行临床评估。在第 3、6 个月和第 1、2、5 年采用磁共振观察软骨修复组织(MOCART)评分评估修复组织的质量。
90.5%(21/21)的患者在第 1 年所有 5 个 KOOS 亚组均有显著改善(P <.05),且在第 5 年仍保持(P <.05)。仅 9.5%(2/21)的患者治疗失败。在第 5 年,IKDC 评分(从 30.1 分提高至 74.3 分)、改良辛辛那提评分(从 38.1 分提高至 79.6 分)和 Tegner-Lysholm 活动评分(从 1.8 分提高至 4.3 分)也有显著改善(P <.05)。同样,MOCART 评分从基线到第 5 年也显著提高(P <.001,从 52.9 分提高至 75.8 分)。5 年后,大多数患者的移植物完全填充(83%)和整合(82%)。5 年后,仍有 47%的患者存在软骨下骨水肿的迹象。在 5 年的随访期间,没有报告与产品相关的不良反应。
采用 MACI 植入物治疗的患者在手术后 5 年时表现出显著的临床改善和良好的修复组织质量。在本研究中,MACI 手术被证明是治疗膝关节症状性创伤性软骨缺损的一种安全有效的方法。